Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2023

Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules

Résumé

Objective Erythromycin is a macrolide antibiotic that is also prescribed off-label in premature neonates as a prokinetic agent. There is no oral formulation with dosage and/or excipients adapted for these high-risk patients. Methods Clinical studies of erythromycin as a prokinetic agent were reviewed. Capsules of 20 milligrams of erythromycin were compounded with microcrystalline cellulose. Erythromycin capsules were analyzed using the chromatographic method described in the United States Pharmacopoeia which was found to be stability-indicating. The stability of 20 mg erythromycin capsules stored protected from light at room temperature was studied for one year. Results 20 mg erythromycin capsules have a beyond use date not lower than one year. Conclusion 20 milligrams erythromycin capsules can be compounded in batches of 300 unities in hospital pharmacy with a beyond-use-date of one year at ambient temperature protected from light.
Fichier principal
Vignette du fichier
journal.pone.0282164_HAL.pdf (646.16 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04480944 , version 1 (27-02-2024)

Identifiants

Citer

Patrick Thevin, Christophe Curti, Alexandre Benech, Christophe Jean, Edouard Lamy, et al.. Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules. PLoS ONE, 2023, 18 (2), pp.e0282164. ⟨10.1371/journal.pone.0282164⟩. ⟨hal-04480944⟩
18 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More